Pure Global

Pharmacokinetics, Biodistribution, Radiation Dose and Safety Study of 68Ga-NYM032 in Patients - Trial NCT06389695

Access comprehensive clinical trial information for NCT06389695 through Pure Global AI's free database. This Phase 1 trial is sponsored by Norroy Bioscience Co., LTD and is currently Recruiting. The study focuses on Prostate Cancer. Target enrollment is 10 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06389695
Phase 1
Recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06389695
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Pharmacokinetics, Biodistribution, Radiation Dose and Safety Study of 68Ga-NYM032 in Patients
Pharmacokinetics, Biodistribution, Radiation Dose and Safety Study of a Single Dose of Gallium [68Ga]-NYM032 Injection Prepared by Kit for the Preparation of the 68Ga-NYM032 Injection in Patients With Prostate Cancer

Study Focus

Prostate Cancer

68Ga-NYM032 injection

Interventional

drug

Sponsor & Location

Norroy Bioscience Co., LTD

Wuxi, China

Timeline & Enrollment

Phase 1

May 01, 2024

Dec 01, 2024

10 participants

Primary Outcome

Incidence of Adverse Events

Summary

68Ga-NYM032 is a PSMA-targeting small-molecular radiotracer for PET/CT imaging of prostate
 cancer, which is needed for clinical trial to be conducted

ICD-10 Classifications

Malignant neoplasm of prostate
Hyperplasia of prostate
Disorder of prostate, unspecified
Other disorders of prostate
Carcinoma in situ: Prostate

Data Source

ClinicalTrials.gov

NCT06389695

Non-Device Trial